Seminars in Hematology
Volume 42, Issue 2 , Pages 76-84, April 2005

Human leukocyte antigen matching in unrelated donor hematopoietic cell transplantation

  • Effie W. Petersdorf

      Affiliations

    • Corresponding Author InformationAddress correspondence to Effie W. Petersdorf, MD, Fred Hutchinson Cancer Research Center, Division of Clinical Research, D4-100, 1100 Fairview Ave N, Seattle, WA 98109
  • ,
  • Mari Malkki

Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA

Hematopoietic cell transplantation (HCT) from unrelated donors is a curative therapy for many malignant and nonmalignant blood disorders. The success of unrelated HCT is influenced by the degree of human leukocyte antigen (HLA) compatibility between the donor and patient. When donor matching for HLA alleles is feasible, overall transplant outcome is superior. The presence of donor-recipient mismatching is associated with increased risk of post-transplant complications including graft rejection, acute and chronic graft-versus-host disease (GVHD), and mortality; these risks are increased with multiple HLA mismatches. For the majority of patients who lack HLA-matched unrelated donors, current research is focused on the identification of permissible HLA mismatches. The influence of nongenetic factors on the tolerability of HLA mismatching has recently become evident, demonstrating a need for the integration of both genetic and nongenetic variables in donor selection.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by Grants CA18029, CA100019, and AI33484 from the National Institutes of Health (E.W.P.); and by Grants CA18029 and AI33484 from the National Institutes of Health, and from the Amy Strelzer Manasevit Scholars Program, National Marrow Donor Program (M.M.).

PII: S0037-1963(05)00009-0

doi:10.1053/j.seminhematol.2005.01.009

Seminars in Hematology
Volume 42, Issue 2 , Pages 76-84, April 2005